Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PSA screening in older men: could it save lives?

NCT ID NCT07206693

Knowledge-focused Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at over 257,000 Swedish men aged 75-79 to see if PSA blood tests for prostate cancer reduce deaths. Since no clinical trials have tested this age group, researchers used existing health records to compare screened and unscreened men. The goal is to find out if screening improves survival and whether guidelines should be updated.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PSA test (prostate-specific antigen blood test)
What this could lead to
If successful, this could show that PSA screening benefits men aged 75-79, potentially expanding screening guidelines to include this age group.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by unmeasured factors. It also cannot fully address the risk of overdiagnosis and unnecessary treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

257,275 people

The number who actually took part.

Started

Jan 2007

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study and the target-trial emulation will use population-based register data of men living in Stockholm between 2007-2023 screened for prostate cancer, extracted from the Stockholm Prostate Cancer Diagnostics Register (STHLM0). STHLM0 has complete PSA test records since 1 January 2007. This will be supplemented with information on non-tested men from the STHLM0+ register. Demographic information, family history of prostate cancer, diagnoses, hospitalization, specialized outpatient healthcare, prostate cancer treatment, and mortality information are provided from the linked Swedish population registers

Ages

75 to 79 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Men aged 75-79 between 2007-2023, with no prostate cancer diagnosis at the time of inclusion (based on each trial emulation) will be considered eligible for the trials. To ensure proper control for potential confounding, and to be able to evaluate the eligibility criteria, only men with complete information on their screening status, outcomes, and confounders in the registers will be included. Exclusion Criteria: Men younger than 75 or older than 79 between 2007-2023. Have prostate cancer diagnosis at the time of inclusion (based on each trial emulation) Missing data on the exposure, outcomes, and confounders.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Prostate cancer screening Prostate cancer screening decision Prostate specific antigen screening

Contacts and locations

Locations

  • Study site

    Stockholm, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.